Vyvanse — Competitive Intelligence Brief

Vyvanse (LISDEXAMFETAMINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central Nervous System Stimulant. Area: Metabolic.

marketed Central Nervous System Stimulant Sodium-dependent dopamine transporter Metabolic Small molecule

Target snapshot

Vyvanse (LISDEXAMFETAMINE) — Takeda. Vyvanse works by blocking the dopamine transporter, allowing more dopamine to be available in the brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vyvanse TARGET	LISDEXAMFETAMINE	Takeda	marketed	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	2007-01-01
Goprelto	COCAINE		marketed	cocaine	Sodium-dependent dopamine transporter	2017-01-01
Datscan	IOFLUPANE I 123	Ge Hlthcare Inc	marketed	Radioactive Diagnostic Agent [EPC]	Sodium-dependent dopamine transporter	2011-01-01
Focalin	DEXMETHYLPHENIDATE	Novartis	marketed	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	2001-01-01
Pemolin	PEMOLINE		marketed	pemoline	Sodium-dependent dopamine transporter	1975-01-01
Norpramin	DESIPRAMINE	Validus Pharms	marketed	Tricyclic Antidepressant	Sodium-dependent dopamine transporter	1964-01-01
Tenuate	DIETHYLPROPION	ANI Pharmaceuticals	marketed	Sympathomimetic Amine Anorectic	Sodium-dependent dopamine transporter	1959-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Central Nervous System Stimulant class)

1. Janssen Research & Development, LLC · 2 drugs in this class
2. Azurity · 1 drug in this class
3. Novartis · 1 drug in this class
4. Takeda · 1 drug in this class
5. UCB · 1 drug in this class